Buy 5F-ADB Online
Synthetic cannabinoids such as 5F-ADB are functionally similar to Δ9-tetrahydrocannabinol (THC), the major psychoactive principle of cannabis. Like THC, they bind to and activate the CB1 and CB2 cannabinoid receptors which form part of the endocannabinoid system. This system helps regulate a large number of physiological functions in the body. This includes; behaviour mood, pain, appetite, sleep, the immune system, and the cardiovascular system. Many synthetic cannabinoids were first developed to study the endocannabinoid system as well as to explore their potential as therapeutic agents. This was to treat a number of diseases and their symptoms such as drug dependence, pain disorders, and cancer.
Herbal smoking mixtures, legal highs, legal cannabis are products containing synthetic cannbinoids which have since 2006 being sold in Europe. Dissolving the synthetic cannabinoids in solvents such as acetone or methanol is a method to make legal highs. Afterwhich, mixing them with, or, spraying them on, plant material such as the herbs Damiana (Turnra diffusa) and Lamiaceae (such as Melissa, Mentha and Thymus).
Psychological and behavioural effects of 5F-ADB
While there is limited data, the psychological and behavioural effects of 5F-ADB appear to share some similarities with cannabis, THC, and other synthetic cannabinoids. This includes: relaxation, euphoria, lethargy, confusion, anxiety, and fear, distorted perception of time, depersonalisation, hallucinations. Equally, paranoia, as well as dry mouth, bloodshot eyes, tachycardia, nausea, vomiting, and impaired motor performance are reported. These effects appear to be much more pronounced and severe when compared to cannabis. In addition, psychotic episodes, as well asaggressive and violent behaviour, have also been reported.
Individual social risks
No specific information on the use of 5F-ADB causes individual social risks, such risks may have some similarities. Higher risk with those associated with cannabis and other synthetic cannabinoids. These may impact on education or career, family or other personal and social relationships and may result in marginalisation.
Description of the control measures that are applicable in the Member States
Fourteen Member States (Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Latvia, Lithuania, Luxembourg, Sweden, and the United Kingdom). Controlled under drug control legislation.